The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, discusses a real-world study examining outcomes of olutasidenib in patients with IDH1-mutated acute myeloid leukemia (AML) previously treated with venetoclax. Dr Cortes reports findings suggesting that prior exposure to venetoclax does not negatively impact responses to olutasidenib. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
